By Fernando Caudevilla (DoctorX)
Pain is a universal experience, but not all pain is the same. Acute pain works as an essential biological defense mechanism that protects the body from injury or threat, while chronic pain, and neuropathic pain in particular, becomes a disease in its own right. In this context, where conventional treatments often fail or carry severe side effects, research on cannabinoids for neuropathic pain has produced solid data that patients and health professionals deserve to know about.
In brief
- Mechanism of action: CB1 and CB2 receptors in the central and peripheral nervous system modulate pain transmission, reducing its reactivity.
- Specific efficacy: The scientific evidence is stronger for neuropathic and inflammatory pain than for other kinds of simple acute pain.
- Therapeutic synergy: Combined use with opioids makes it possible to lower opioid doses, minimizing adverse effects such as dependence or respiratory depression.
- Safety profile: Side effects such as dizziness or sedation are usually temporary and tolerance develops; they do, however, call for an individual assessment of psychological risk.
- Unequal access: There is a significant disparity in the availability of these treatments between countries, despite similar clinical evidence.
Types of Pain: Beyond a Simple Sensation
To understand the therapeutic value of cannabis, it is essential to distinguish between the different causes of pain. It is not simply an alarm signal but a set of complex physiological processes:
Visceral and Inflammatory Pain
Visceral pain (from hollow organs) and inflammatory pain (injuries with edema) generally respond well to standard protocols. The body releases molecules that cause swelling, heat, and pain to immobilize the area and promote healing. These processes can be managed with anti-inflammatories or traditional analgesics.
Neuropathic Pain: The Clinical Challenge
The situation changes dramatically with neuropathic pain. Here, the nerve fibers themselves are damaged. The nervous system sends pain signals without any active tissue injury; it is as if the alarm were sounding when there is no fire. Conditions such as postherpetic neuralgia (after shingles), diabetic neuropathy, multiple sclerosis, and the phantom limb phenomenon fall into this category. Typical features include burning, coldness, numbness, and a “pins and needles” sensation. Statistically, only 40% to 50% of patients achieve an acceptable quality of life with current therapies.
The Science Behind the Relief: Cannabinoid Receptors
Why do cannabinoids work in this scenario? The answer lies in basic pharmacology. The human body has its own endocannabinoid system, regulated by CB1 receptors (mainly in the brain and spinal cord) and CB2 receptors (in immune and peripheral cells). These receptors act as switches that modulate the release of pain neurotransmitters.
Preclinical and clinical studies have shown that cannabinoids, both exogenous and endogenous (such as anandamide), bind to these receptors to “calm” overexcited neurons. This results in a direct decrease in the transmission of neuropathic and inflammatory pain.
Clinical Evidence and Controlled Trials
The scientific literature offers concrete data on the use of synthetic and natural cannabinoids:
- Dronabinol (synthetic THC): In a randomized study of patients being treated with morphine or fentanyl, adding dronabinol significantly improved relief of chronic non-cancer pain.
- Nabilone: This synthetic agonist has shown particularly notable efficacy in managing cancer pain and associated symptoms.
- Smoked or vaporized cannabis: Although the studies are smaller, a placebo-controlled trial showed that preparations with high THC concentrations (around 9%) improved post-traumatic neuropathic pain and sleep quality.
- Multiple sclerosis: Several international protocols endorse its use to reduce spasticity and pain in patients with multiple sclerosis, although local regulations vary enormously.
Harm Reduction Strategies and Safety Profile
Like any drug, medical cannabis has a profile of adverse effects that must be managed with care:
Temporary Physical Effects
Dizziness, sedation, and drowsiness are the most frequent side effects. In most cases, however, the body develops tolerance to these symptoms after a few weeks of continuous treatment, making it possible to maintain the therapeutic dose without discomfort.
Psychological Risks
The emotional response to cannabis varies. While some patients experience a euphoria that helps them disconnect from chronic pain and improves their mood, others may develop anxiety, distress, or an increased focus on the pain (hyperalgesia). These effects depend on individual factors such as genetics, psychiatric history, and personality. It is crucial to stop treatment if significant adverse psychological reactions appear.
The Future: Non-Psychoactive Cannabinoids
Research is moving toward compounds such as CT-3 (ajulemic acid), a synthetic analog that promises analgesic effects without altering the state of consciousness. This is the pharmacological “holy grail”: relieving pain without the associated psychoactive effects.
Thoughts on Self-Medication and Access
It is undeniable that a significant share of patients with chronic pain turn to unregulated sources (hashish or marijuana) out of desperation after other therapies have failed. The scientific data support the idea that cannabis can be effective, but this does not justify self-medication without medical supervision.
The disparity in access to these treatments is troubling: while in some nations cannabinoid sprays are approved for neuropathic pain or muscle stiffness in multiple sclerosis, other countries restrict their use. This situation shows how scientific evidence collides with regulatory barriers and cultural prejudice.
Conclusion: Toward a Compassionate Medicine
Neuropathic pain should not be accepted as an inevitable fate or treated only with palliatives. Cannabinoids are one more tool in the therapeutic arsenal, and they should be integrated in a personalized and responsible way.
Despite the accumulated evidence on their efficacy and relative safety, attitudes based on irrational fears or outdated moralizing persist. Modern medicine demands that people’s rights and the relief of suffering come before unfounded prejudice. Facilitating rigorous research and guaranteeing equitable access to treatments of proven efficacy is not only a clinical necessity but an ethical imperative to improve the quality of life of millions of patients who suffer in silence.
